Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Feb 5, 2024

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Feb 1, 2024

Sanofi launches Beyfortus® (nirsevimab-alip) Reservation Program for 2024-2025 RSV season in U.S.
Jan 25, 2024

Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Jan 16, 2024

Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement
Dec 14, 2023

Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Dec 13, 2023

Study: Sanofi Flublok® Quadrivalent (Influenza Vaccine) provides better protection against flu infection versus standard dose in adults ages 50-64
Dec 11, 2023

Sarclisa® (isatuximab-irfc) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Dec 7, 2023

Sarclisa® (isatuximab-irfc) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Nov 17, 2023

Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Nov 7, 2023

Sanofi to present clinical data reinforcing commitment to scientific innovation across blood cancers and rare blood disorders at ASH 2023

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.